PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, ...

O RLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective cohort study linked GLP-1 receptor agonists to a lower risk of legal blindness ...

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

Here’s the good news: The GLP-1 class of weight-loss drugs is so powerful that, in 20 years, those drugs can save millions from premature death, a leading insurance company says. That’s also the bad ...

Along with cost, education around total rewards is also a part of the Q4 benefits conversation.

Five systemic drugs, including fingolimod and apixaban, were identified with under-recognized maculopathy risks using ...

Paclitaxel-coated vs. uncoated devices did not reduce amputations in patients with chronic limb-threatening ischemia and ...

Treatment of significant musculoskeletal symptoms with NSAIDs may be acceptable for certain patients with inflammatory bowel disease.